Ovid Therapeutics Inc. Contracts & Agreements

Non-Employee Director Compensation Policy, effective May 5, 2022 (Filed With SEC on May 10, 2022)

License Agreement, dated as of December 30, 2021, by and between the Ovid Therapeutics Inc. and AstraZeneca AB (Filed With SEC on January 3, 2022)

Non-Employee Director Compensation Policy, effective May 6, 2021 (Filed With SEC on November 10, 2021)

Amended and Restated Executive Employment Agreement between the Company and Jeffrey Rona, effective June 2, 2021 (Filed With SEC on August 16, 2021)

Royalty, License and Termination Agreement, by and between the Company and Takeda Pharmaceutical Company Limited, dated March 2, 2021 (Filed With SEC on May 13, 2021)

Executive Employment Agreement between the Company and Jeff Rona, effective September 30, 2020 (Filed With SEC on March 15, 2021)

Executive Employment Agreement between the Company and Jason Tardio, effective October 21, 2019 (Filed With SEC on March 15, 2021)

Amended and Restated Executive Employment Agreement between the Company and Thomas Perone, effective January 1, 2020 (Filed With SEC on March 15, 2021)

Collaboration and License Agreement, by and between the Company and Angelini Pharma Rare Diseases AG, dated July 9, 2020 (Filed With SEC on March 15, 2021)

Collaboration and License Agreement, by and between the Company and Angelini Pharma Rare Diseases AG, dated July 9, 2020 (Filed With SEC on November 13, 2020)

Underwriting Agreement related to the Offering, dated August 25, 2020, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on August 26, 2020)

Description of the Securities of Ovid Therapeutics Inc (Filed With SEC on March 11, 2020)

Non-Employee Director Compensation Plan (Filed With SEC on March 11, 2020)

Second Amended and Restated Executive Employment Agreement between the Company and Amit Rakhit, effective November 1, 2019 (Filed With SEC on March 11, 2020)

Third Amended and Restated Executive Employment Agreement between the Company and Tim Daly, effective December 18, 2019 (Filed With SEC on March 11, 2020)

Underwriting Agreement related to the Common Offering, dated October 4, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on October 8, 2019)

Underwriting Agreement related to the Preferred Offering, dated October 4, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on October 8, 2019)

Exchange Agreement among Ovid Therapeutics Inc. and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P., dated... (Filed With SEC on September 19, 2019)

Lundbeck Amendment (Filed With SEC on June 17, 2019)

Separation and Consulting Agreement, by and between the Company and Matthew During, dated as of March 24, 2019 (Filed With SEC on May 7, 2019)

Underwriting Agreement related to the Common Offering, dated February 20, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on February 21, 2019)

Underwriting Agreement related to the Preferred Offering, dated February 20, 2019, among Ovid Therapeutics Inc. and Cowen and Company, LLC and William Blair & Company, L.L.C (Filed With SEC on February 21, 2019)

Form of Series A Preferred Stock Certificate (Filed With SEC on February 21, 2019)

Amended and Restated Executive Employment Agreement between the Registrant and Matthew During (Filed With SEC on May 8, 2018)

Amended and Restated Executive Employment Agreement between the Registrant and Yaron Werber (Filed With SEC on May 8, 2018)

License Agreement by and between Northwestern University and the Registrant, dated December 15, 2016 (Filed With SEC on March 29, 2018)

INDEMNITY AGREEMENT (Filed With SEC on May 3, 2017)

LICENSE AGREEMENT BETWEEN H. LUNDBECK A/S AND OVIDTHERAPEUTICS INC. (Filed With SEC on May 2, 2017)

Signature(s) Guaranteed: Medallion Guarantee Stamp (Filed With SEC on April 25, 2017)

Ovid Therapeutics Inc. [] Shares Common Stock ($0.001 par value) Underwriting Agreement (Filed With SEC on April 18, 2017)

INDEMNITY AGREEMENT (Filed With SEC on April 18, 2017)

OVID THERAPEUTICS INC. 2017 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 2017 APPROVED BYTHE STOCKHOLDERS: , 2017 IPODATE: , 2017 (Filed With SEC on April 18, 2017)

OVID THERAPEUTICS INC. STOCK OPTION GRANT NOTICE (2017 EQUITY INCENTIVE PLAN) (Filed With SEC on April 18, 2017)

OVID THERAPEUTICS INC. 2017 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:[ ] APPROVED BY THE STOCKHOLDERS:[ ] (Filed With SEC on April 18, 2017)

AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on April 18, 2017)

SECOND AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT TABLE OF CONTENTS (Filed With SEC on April 10, 2017)

OVID THERAPEUTICS INC. 2014 EQUITY INCENTIVE PLAN (Filed With SEC on April 10, 2017)

AMENDMENT TO OVIDTHERAPEUTICS INC. 2014 EQUITY INCENTIVE PLAN (Filed With SEC on April 10, 2017)

AMENDMENT TO OVID THERAPEUTICS INC. 2014 EQUITY INCENTIVE PLAN (Filed With SEC on April 10, 2017)

OVID THERAPEUTICS INC. 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK PURCHASE AGREEMENT (Filed With SEC on April 10, 2017)

OVID THERAPEUTICS INC. 2014 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT EARLY EXERCISE (Filed With SEC on April 10, 2017)

OVID THERAPEUTICS INC. 2014 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (Filed With SEC on April 10, 2017)

LICENSE AGREEMENT BETWEEN H. LUNDBECK A/S AND OVIDTHERAPEUTICS INC. (Filed With SEC on April 10, 2017)

LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN TAKEDAPHARMACEUTICAL COMPANY LIMITED AND OVID THERAPEUTICS INC. JANUARY 6, 2017 Table of Contents (Filed With SEC on April 10, 2017)

SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT TABLE OF CONTENTS (Filed With SEC on April 10, 2017)